Aortic Valve Disease Clinical Trial
— ASCENDOfficial title:
ASCEND - Post Market Clinical Follow-Up Study in Patients Treated With the On-X Ascending Aortic Prosthesis (AAP)
Verified date | January 2024 |
Source | JOTEC GmbH |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
The ASCEND post-market clinical follow-up study is undertaken to evaluate safety and clinical performance of the On-X Ascending Aortic Prosthesis (AAP) used in surgical aortic valve replacement.
Status | Active, not recruiting |
Enrollment | 108 |
Est. completion date | March 31, 2029 |
Est. primary completion date | March 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient = 18 years of age at time of On-X AAP implant - Patient understands and has signed the Informed Consent Form: - Prior to implant of On-X AAP or - Post implant (US only) or - Patient died prior to enrollment (US only) - Patient is willing and able to participate in follow-up Exclusion Criteria: - Patient unable to tolerate anticoagulation therapy - Patient with active endocarditis at the time of his / her On-X AAP implant - Patient participates / participated in another clinical investigation which may interfere / may have interfered with the effectiveness of anticoagulation therapy - Patient has anomalous anatomy or medical, surgical, psychological or social history or conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation results - Patients in which On-X AAP is implanted in combination with AMDS or FET - Patient's life expectancy is less than 3 years in the opinion of the Investigator |
Country | Name | City | State |
---|---|---|---|
Germany | Medizinische Hochschule Hannover (MHH) | Hannover | |
Germany | University Hospital Magdeburg | Magdeburg | |
Italy | Policlinico S. Orsola-Malpighi | Bologna | |
Spain | Hospital Germans Trias i Pujol | Badalona | |
Spain | Hospital de la Santa Creu i Sant Pau | Barcelona | |
United Kingdom | Castle Hill Hospital | Cottingham | |
United Kingdom | St Bartholomew's Hospital | London | |
United Kingdom | Newcastle Freeman Hospital | Newcastle | |
United States | Geisinger Health System | Danville | Pennsylvania |
United States | Baylor College of Medicine | Houston | Texas |
United States | VCU Medical Center Main Hospital | Richmond | Virginia |
Lead Sponsor | Collaborator |
---|---|
JOTEC GmbH |
United States, Germany, Italy, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mortality | Rate of in-house all-cause mortality | 30-day | |
Secondary | All-cause Mortality | Rate of all-cause mortality | 30-day, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years | |
Secondary | Valve-related mortality | Rate of valve-related mortality | 30-day, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years | |
Secondary | Reoperation | Rate of patients with reoperation | 30-day, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years | |
Secondary | Explant | Rate of patients with explant of On-X AAP (including heart valve) | 30-day, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years | |
Secondary | Endocarditis | Rate of patients with endocarditis | 30-day, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years | |
Secondary | Embolism | Rate of patients with embolism | 30-day, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years | |
Secondary | Thromboembolism | Rate of patients with peripheral thromboembolism | 30-day, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years | |
Secondary | Bleeding | Rate of patients with major bleeding | 30-day, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years | |
Secondary | Transient ischemic attack | Rate of patients with transient ischemic attack (TIA) | 30-day, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years | |
Secondary | Stroke | Rate of patients with new stroke (ischemic and hemorrhagic) (mRS > mRS at baseline) | 30-day, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years | |
Secondary | Ischemic stroke | Rate of patients with new ischemic stroke (mRS > mRS at baseline) | 30-day, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years | |
Secondary | Hemorrhagic stroke | Rate of patients with new hemorrhagic stroke (mRS > mRS at baseline) | 30-day, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years | |
Secondary | Valve deterioration | Rate of patients with structural valve deterioration | 30-day, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years | |
Secondary | Non-structural dysfunction | Rate of patients with non-structural dysfunction | 30-day, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years | |
Secondary | Valve thrombosis | Rate of patients with valve thrombosis | 30-day, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years | |
Secondary | NYHA | NYHA Functional Class | 1 year, 3 years, 5 years, 10 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04149600 -
Identification of Genetic Causes of Calcific Aortic Valve Disease
|
||
Recruiting |
NCT06001489 -
The Effects of 360-degree Virtual Reality on Pre-procedural Anxiety in Patients Awaiting Elective Cardiac Surgery Involving a Sternotomy
|
N/A | |
Not yet recruiting |
NCT04430972 -
Immune Responsiveness and Outcome After Aortic Valve Surgery (Measure)
|
||
Completed |
NCT02467062 -
Implementation of Non-size Markers Derived From 4D Flow MRI of Patients With Aortic Disease.
|
N/A | |
Not yet recruiting |
NCT02221921 -
Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI
|
N/A | |
Terminated |
NCT02128841 -
Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.
|
Phase 2 | |
Active, not recruiting |
NCT01194362 -
A Study to Identify Differences in Gene Expression in Patients With Bicuspid and Tricuspid Valve Disease
|
||
Not yet recruiting |
NCT05975567 -
Deploying Novel Imaging Modalities Towards a Three-dimensional (3D) CARDIOvascular PATHology
|
||
Recruiting |
NCT06025149 -
The Study on the Use of "UniLine" Bioprosthesis in the Treatment of Isolated Aortic and Mitral Valve Diseases
|
||
Completed |
NCT05082337 -
The SAVVY Guidewire in Transcatheter Aortic Valve Replacement Procedures
|
N/A | |
Completed |
NCT05193760 -
Robustness Check of Placement and Measurement Algorithms for Blood Flow Measurement on Common Carotid Artery
|
||
Not yet recruiting |
NCT05941455 -
A Prospective Multicenter Pivotal Study to Evaluate Safety and Effectiveness of Venus-Neo Surgical Aortic Valve
|
N/A | |
Active, not recruiting |
NCT04950192 -
Philips Intracardiac Echocardiography (ICE) Clinical Registry
|
||
Active, not recruiting |
NCT03924661 -
SJM Masters HP 15mm Rotatable Mechanical Heart Valve as Aortic Valve Replacement Therapy
|
||
Completed |
NCT04073875 -
18F-GP1 PET-CT to Detect Bioprosthetic Aortic Valve Thrombosis
|
||
Recruiting |
NCT03121053 -
Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement
|
Phase 4 | |
Completed |
NCT02000544 -
Clinical Evaluation of a Modular Extracorporeal Circulation Circuit
|
N/A | |
Completed |
NCT02688153 -
EDWARDS INTUITY Valve System CADENCE Study
|
N/A | |
Completed |
NCT02981004 -
PAR I - Patient-to-Annulus Relation I
|
||
Recruiting |
NCT06126367 -
Assessment of Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic Cardiovascular Disease/Aortic Valve Disease
|